2018
DOI: 10.1007/s00705-018-4066-5
|View full text |Cite
|
Sign up to set email alerts
|

Molecular diagnosis of occult hepatitis C virus infection in Iranian injection drug users

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 7 publications
(3 citation statements)
references
References 51 publications
0
3
0
Order By: Relevance
“…Residual HCV-RNA has been detected in populations free of markers of ongoing HCV infection and previous exposure to the virus. Persisting HCV was found in high-risk groups such as injection drug users-9.6-18.2% [77,78], patients with beta-thalassemia major-3.3-6.3% [38,79], hemodialysis patients-4.8-45% [80,81], or infectious liver disease-free subjects undergoing phlebotomy-1.27% [82]. A recent meta-analysis of studies on populations from the Middle East and Eastern Mediterranean countries estimated the pooled rate of OCI in patients diagnosed with cryptogenic liver disease to be 20.8% [83].…”
Section: Epidemiological Significance Of Ocimentioning
confidence: 99%
“…Residual HCV-RNA has been detected in populations free of markers of ongoing HCV infection and previous exposure to the virus. Persisting HCV was found in high-risk groups such as injection drug users-9.6-18.2% [77,78], patients with beta-thalassemia major-3.3-6.3% [38,79], hemodialysis patients-4.8-45% [80,81], or infectious liver disease-free subjects undergoing phlebotomy-1.27% [82]. A recent meta-analysis of studies on populations from the Middle East and Eastern Mediterranean countries estimated the pooled rate of OCI in patients diagnosed with cryptogenic liver disease to be 20.8% [83].…”
Section: Epidemiological Significance Of Ocimentioning
confidence: 99%
“…5 OCI has been described in patients with chronic liver disease, coinfections, comorbidities and in population with risk factors, such as, in patients infected with hepatitis B virus or human immunodeficiency virus, with tattoos, drugs users, and apparently in healthy population. [6][7][8][9][10][11] The primary goal of HCV therapy is to cure the infection, i.e. to achieve a sustained virological response (SVR) defined as undetectable HCV-RNA in serum after treatment completion, and the use of direct-acting antiviral agents (DAAs) markedly improved the SVR rates.…”
Section: Introductionmentioning
confidence: 99%
“…In recent years, Direct-acting Antiviral Agents (DAAs) have been approved for treating HCV. These drugs can achieve HCV clearance in up to 98% of cases with a favorable clinical impact on hepatic and extrahepatic manifestations (3,4). Yet, an estimated 1.5 -2 million new HCV infections occur globally each year (5).…”
Section: Introductionmentioning
confidence: 99%